Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 7, 2016, Pages 623-629

  Bozzetto, L ^a   Annuzzi, G ^a   Ragucci, M ^a   Di Donato, O ^a   Della Pepa, G ^a   Della Corte, G ^a   Griffo, E ^a   Anniballi, G ^a   Giacco, A ^a   Mancini, M ^b   Rivellese, A A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

GLP 1; HDL; IFN g; Inflammation; Insulin resistance; NAFLD

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 17; INTERLEUKIN 4; LIPOPROTEIN; POLYPHENOL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IFNG PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIETARY COMPLIANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; DIET THERAPY; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; ITALY; LIVER; MEDICAL RECORD; METABOLISM; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

ADAPTIVE IMMUNITY; ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIET RECORDS; FEEDING BEHAVIOR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERFERON-GAMMA; ITALY; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; POSTPRANDIAL PERIOD; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84964599054     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.01.011     Document Type: Article

References (30)

1. Loria P., Lonardo A., Bellentani S., Day C.P., Marchesini G., Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007, 17(9):684-698.
2. Gaggini M., Morelli M., Buzzigoli E., DeFronzo R.A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5(5):1544-1560.
3. Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr 2014, 33(2):186-190.
4. Smith B.W., Adams L.A. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011, 7(8):456-465.
5. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000.
6. Bozzetto L., Prinster A., Mancini M., Giacco R., De Natale C., Salvatore M., et al. Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. Eur J Clin Invest 2011, 41(1):39-44.
7. Rijkelijkhuizen J.M., Doesburg T., Girman C.J., Mari A., Rhodes T., Gastaldelli A., et al. Hepatic fat is not associated with beta-cell function or postprandial free fatty acid response. Metabolism 2009, 58(2):196-203.
8. Finucane F.M., Sharp S.J., Hatunic M., Sleigh A., De Lucia Rolfe E., Aihie Sayer A., et al. Liver fat accumulation is associated with reduced hepatic insulin extraction and beta cell dysfunction in healthy older individuals. Diabetol Metab Syndr 2014, 6(1):43.
9. Alssema M., Rijkelijkhuizen J.M., Holst J.J., Teerlink T., Scheffer P.G., Eekhoff E.M., et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol 2013, 169(4):421-430.
10. Cuthbertson D.J., Irwin A., Gardner C.J., Daousi C., Purewal T., Furlong N., et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012, 7(12):e50117.
11. Matikainen N., Mänttäri S., Westerbacka J., Vehkavaara S., Lundbom N., Yki-Järvinen H., et al. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007, 92(8):3052-3059.
12. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846.
13. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
15. Annuzzi G., Bozzetto L., Costabile G., Giacco R., Mangione A., Anniballi G., et al. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. Am J Clin Nutr 2014, 99(3):463-471.
16. Mancini M., Prinster A., Annuzzi G., Liuzzi R., Giacco R., Medagli C., et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009, 58(12):1724-1730.
17. Rivellese A.A., De Natale C., Di Marino L., Patti L., Iovine C., Coppola S., et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004, 89(5):2153-2159.
18. Di Marino L., Griffo E., Maione S., Mirabella M. Active glucagon-like peptide-1 (GLP-1): storage of human plasma and stability over time. Clin Chim Acta 2011, 412(17-18):1693-1694.
19. Pacini G., Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003, 17(3):305-322.
20. Kotronen A., Juurinen L., Tiikkainen M., Vehkavaara S., Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008, 135(1):122-130.
21. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50(8):1844-1850.
22. Kahl S., Straßburger K., Nowotny B., Livingstone R., Klüppelholz B., Keßel K,Hwang J.H., et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014, 9(4):e94059.
23. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012, 32(1):22-29.
24. Vergès B., Adiels M., Boren J., Barrett P.H., Watts G.F., Chan D., et al. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J Clin Endocrinol Metab 2014, 99(11):4281-4290.
25. Bernsmeier C., Meyer-Gerspach A.C., Blaser L.S., Jeker L., Steinert R.E., Heim M.H., et al. Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with non- alcoholic fatty liver disease. PLoS One 2014, 9(1):e87488.
26. Seino Y., Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013, 4(2):108-130.
27. Xiao C., Bandsma R.H., Dash S., Szeto L., Lewis G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012, 32(6):1513-1519.
28. Asrih M., Jornayvaz F.R. Inflammation as a potential link between non-alcoholic fatty liver disease and insulin resistance. J Endocrinol 2013, 218(3):R25-R36.
29. Vonghia L., Michielsen P., Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci 2013, 14(10):19867-19890.
30. Kisseleva T. Does interleukin-17 play the villain in non-alcoholic steatohepatitis?. Hepatology 2014, 59(5):1671-1672.